Рынок промежуточных API на Ближнем Востоке и в Африке – тенденции отрасли и прогноз до 2028 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок промежуточных API на Ближнем Востоке и в Африке – тенденции отрасли и прогноз до 2028 года

  • Pharmaceutical
  • Published Report
  • Apr 2021
  • MEA
  • 350 Pages
  • Количество таблиц: 95
  • Количество рисунков: 50

Рынок промежуточных продуктов API на Ближнем Востоке и в Африке по типу (промежуточные продукты для ветеринарных препаратов, фармацевтические препараты / промежуточные продукты для оптовых партий лекарств), продукт (бромсоединение, O-бензилсальбутамол, гемисульфат, оксиран, основание бисопролола, хиральный PCBHP, основание фенирамина, основание хлорфенирамина, основание бромфенирамина, основание мепирамина/пириламина, 6-амино-1,3-диметилурацил, теофиллин, ацефиллин, ксантин, нитрилы и другие), терапевтический тип (аутоиммунные заболевания, онкология, метаболические заболевания, офтальмология, сердечно-сосудистые заболевания, инфекционные заболевания, неврология, респираторные заболевания, дерматология, урология и другие), клиенты (прямые пользователи/фармацевтические компании, трейдеры/оптовики/дистрибьюторы, ассоциации/правительство. Учреждения/частные учреждения), конечный пользователь (производитель API, производитель готовой продукции), канал сбыта (прямой тендер, розничные продажи, другие), страна (Саудовская Аравия, Южная Африка, ОАЭ, Израиль, Кувейт, Египет, остальные страны Ближнего Востока и Африки). Тенденции развития отрасли и прогноз до 2028 г.

Рынок промежуточных продуктов API на Ближнем Востоке и в Африке

Анализ рынка и аналитика : рынок промежуточных продуктов API на Ближнем Востоке и в Африке

Ожидается, что рынок промежуточных АФИ на Ближнем Востоке и в Африке будет расти в прогнозируемый период с 2021 по 2028 год. По данным Data Bridge Market Research, рынок будет расти со среднегодовым темпом роста 5,3% в прогнозируемый период с 2021 по 2028 год и, как ожидается, достигнет 1 188,62 млн долларов США к 2028 году. Основными факторами, обусловившими рост спроса на рынке в прогнозируемый период, являются высокое бремя хронических заболеваний и рост старения населения.

Активные фармацевтические ингредиенты — это вещество или комбинация веществ, предназначенных для использования в производстве лекарственного продукта, которые при использовании в производстве препарата становятся активным фармацевтическим ингредиентом. Такие вещества используются для обеспечения фармакологической активности. Окончательная лекарственная форма изготавливается с использованием API и вспомогательного вещества, но API изготавливаются с использованием сырья, которое известно как промежуточные продукты. Промежуточные продукты API — это вид материала, который производится в процессе API. Промежуточные продукты являются побочным продуктом активных фармацевтических ингредиентов и обеспечивают ту же терапевтическую активность, что и API. Эти промежуточные продукты также используются для лечения различных видов хронических заболеваний, таких как рак, респираторные заболевания и инфекционные заболевания среди прочих.

Промежуточные продукты API — это агенты или соединения, которые используются в качестве сырья для формулирования или производства активных фармацевтических ингредиентов. Эти промежуточные продукты подвергаются очистке или молекулярным изменениям для формирования конечного API. В производстве промежуточных продуктов задействованы различные технологии, такие как аминирование, алкоксилирование, электрохимия, гидрирование, гидроформилирование, химия ацетилена, химия фосгена и другие технологии.

The API intermediates market is growing with the increasing prevalence of various chronic disorders and the increasing aging population. Moreover, increasing research and development regarding pharmaceutical APIs and their intermediates are other factors accelerating the API intermediates market growth.

The API intermediates market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Рынок промежуточных продуктов API на Ближнем Востоке и в Африке

Middle East and Africa API Intermediates Market Scope and Market Size

API intermediates market is segmented on the based on the basis of type, product, therapeutic type, customers, end users, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, API intermediates market is segmented into veterinary drug intermediates pharmaceutical / bulk drug intermediates. In 2021, pharmaceutical / bulk drug intermediates is expected to dominate the API intermediates market due to rising demand of APIs for the production of finished goods and rising prevalence of various diseases which required continues production of drugs.
  • On the basis of product, API intermediates market is segmented into bromo compound, O-benzyl salbutamol, hemisulfate, oxirane, bisoprolol base, chiral PCBHP, pheniramine base, chlorpheniramine base, brompheniramine base, mepyramine/pyrilamine base, 6-amino-1,3-dimethyl uracil, theofylline, acefylline, xanthine, nitriles, and others. In 2021, nitriles segment is expected to dominate the API intermediates market due to the high cost of the products and continues research and development for the innovative APIs.
  • On the basis of therapeutic type, API intermediates market is segmented into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, urology, and others. In 2021, cardiovascular diseases segment is expected to dominate the API intermediates market because cardiovascular is the leading cause of death globally.
  • On the basis of customers, API intermediates market is segmented direct users/pharma companies, traders/wholesalers/distributors, and associations/govt. institutions/Pvt institutions. In 2021, direct users/pharma companies segment is expected to dominate the API intermediates market because APIs manufacture are the primary and direct user for the intermediates. Rising Contract manufacturing also boost the market.
  • On the basis of end user, API intermediates market is segmented into API manufacturer, and finished product manufacturer. In 2021, API manufacturer segment is dominating the API intermediates market because intermediates are the primary chemical substrate of the APIs, which can be further converted in APIs. So, the intermediates is widely used by the API manufacturer to reduce the cost of manufacturing.
  • On the basis of distribution channel, API intermediates market is segmented into direct tender, retail sales, and others. In 2021, direct tender is expected to dominate the API intermediates market because direct tender provides huge margin for the purchase good and direct tender has competitive selection of contract and consultants there is accountability.

API Intermediates Market Country Level Analysis

The API intermediates market is analyzed and market size information is provided on the basis of type, product, therapeutic type, customers, end users, and distribution channel as referenced above.

The countries covered in the API intermediates market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa.

Saudi Arabia is leading the growth of the Middle East and Africa region due to increasing prevalence of various chronic disorders in the country.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Research and Development Regarding Pharmaceutical APIs and their intermediates and Increasing Disease Awareness and Education are boosting the Market Growth of API Intermediates

API intermediates market also provides you with detailed market analysis for every country growth in API intermediates industry with API intermediates drugs sales, impact of advancement in the API intermediates technology and changes in regulatory scenarios with their support for the API intermediates market. The data is available for historic period 2010 to 2019.

Анализ конкурентной среды и доли рынка промежуточных API

Конкурентная среда рынка промежуточных API содержит подробную информацию по конкурентам. Включены следующие сведения: обзор компании, финансовые показатели компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, испытания продуктов, одобрения продуктов, патенты, широта и широта продукта, доминирование приложений, кривая жизненного цикла технологии. Приведенные выше данные относятся только к фокусу компании на рынке промежуточных API.

Основными компаниями, работающими с промежуточными продуктами АФИ, являются Sanofi, Aurobindo Pharma, BASF SE, Vasudha Pharma, Anyang General Chemical Co., Ltd., Sandoo Pharmaceuticals and Chemicals Co., Ltd., Atul Ltd., Supriya Lifescience Ltd. и др. Аналитики DBMR понимают конкурентные преимущества и предоставляют конкурентный анализ для каждого конкурента в отдельности.

Многие запуски продуктов и соглашения также инициируются компаниями по всему миру, что также ускоряет развитие рынка промежуточных АФИ.

Например,

  • В ноябре 2020 года AlzChem Group AG объявила о расширении производства нитрилов, которые являются одним из промежуточных продуктов компании. Компания решила расширить производство на 50%. Мотивом компании было удовлетворение спроса на лекарства и биоциды. Завод по производству нитрилов основан на газофазной технологии, которая была оптимизирована и проверена инженерами компании. Это расширение помогло компании усилить свой рост в области промежуточных продуктов, что поможет им увеличить свои производственные мощности.
  • В апреле 2020 года Aceto объявила о приобретении Syntor Fine Chemicals, одного из ведущих производителей тонкой химии, которая используется в фармацевтической промышленности и конечных рынках наук о жизни. Это приобретение помогло компании увеличить рост рынка, поскольку Syntor Fine Chemicals будет поставлять компании свою собственную разработанную продукцию, поэтому обе компании будут работать вместе, чтобы удовлетворить растущий спрос клиентов.

Сотрудничество, запуск продукции, расширение бизнеса, награды и признание, совместные предприятия и другие стратегии участников рынка расширяют возможности компании на рынке промежуточных API, что также дает организациям возможность улучшить свое предложение промежуточных API.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET TYPE COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 CURRENT SCENARIO OF IMPORT AND EXPORT OF API INTERMEDIATE

4.2 TENTATIVE PRODUCTION AND OPERATIONAL COSTS CALCULATIONS WHICH WILL ULTIMATELY LEAD TO FEASIBILITY OF THE PRODUCT MANUFACTURING

4.2.1 TENTATIVE LAND REQUIREMENT FOR A SUBSTANTIAL PRODUCTION CAPACITY PLANT SET-UP

4.3 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: 3C ANALYSIS-CHINA EFFECT

4.3.1 THE U.S.-CHINA TRADE WAR

4.3.2 INDO-CHINA GEOPOLITICAL ISSUES

4.3.3 CHINESE SLOWDOWN DUE TO E&C OVER THE YEARS

4.3.4 CHINESE SLOWDOWN DUE TO COVID-19 (CORONAVIRUS)

4.4 COST ANALYSIS

4.5 ANALYSIS ON CHINA API INTERMEDIATES:

4.5.1 CONCLUSION:

4.6 PORTERS FIVE FORCES MODEL

4.7 PESTEL ANALYSIS

4.8 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: REGULATORY

4.8.1 THE U.S. REGULATORY GUIDANCE FOR NON-CLINICAL SAFETY EVALUATION OF API INTERMEDIATES

4.8.2 CANADA REGULATORY GUIDANCE FOR API INTERMEDIATES

4.8.3 EUROPE REGULATORY SCENARIO FOR API INTERMEDIATES

4.8.4 JAPAN REGULATORY FOR API INTERMEDIATES

4.8.5 MIDDLE EAST AND AFRICA REGULATORY FRAMEWORK FOR API INTERMEDIATES

5 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: CONCLUSION

5.1 TOP PRODUCTS AND THERAPEUTIC AREAS

5.2 ADDITIONAL

6 CUSTOMER SENTIMENTS/INCLINATION TOWARDS FINDING ALTERNATE VENDOR SOURCE

7 LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE:

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 HIGH BURDEN OF CHRONIC DISEASES

8.1.2 INCREASE IN AGING POPULATION

8.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING

8.1.4 INCREASING DISEASE AWARENESS AND EDUCATION

8.1.5 RESEARCH AND DEVELOPMENT REGARDING PHARMACEUTICAL API AND THEIR INTERMEDIATES

8.2 RESTRAINTS

8.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS

8.2.2 PRODUCT RECALLS

8.2.3 HIGH MANUFACTURING COST

8.2.4 STRINGENT GOVERNMENT REGULATIONS FOR API INTERMEDIATES

8.3 OPPORTUNITIES

8.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS

8.3.2 INCREASING HEALTHCARE EXPENDITURE

8.3.3 SOARING NUMBER OF API INTERMEDIATES MANUFACTURERS

8.3.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO)

8.4 CHALLENGES

8.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19

8.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES

9 IMPACT OF COVID 19 ON MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET

9.1 IMPACT ON PRICE

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY CHAIIN

9.4 STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE

9.5 CONCLUSION

10 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY TYPE

10.1 OVERVIEW

10.2 PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES

10.3 VETERINARY DRUG INTERMEDIATES

11 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY PRODUCT

11.1 OVERVIEW

11.2 NITRILES

11.3 BROMO COMPOUND

11.4 CHIRAL PCBHP

11.5 CHLORPHENIRAMINE BASE

11.6 BROMPHENIRAMINE BASE

11.7 PHENIRAMINE BASE

11.8 O-BENZYL SALBUTAMOL

11.9 BISOPROLOL BASE

11.1 HEMISULFATE

11.11 OXIRANE

11.12 MEPYRAMINE/PYRILAMINE BASE

11.13 THEOFYLLINE

11.14 ACEFYLLINE

11.15 XANTHINE

11.16 6-AMINO-1,3-DIMETHYL URACIL

11.17 OTHERS

12 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE

12.1 OVERVIEW

12.2 CARDIOVASCULAR DISEASES

12.3 METABOLIC DISEASES

12.4 INFECTIOUS DISEASES

12.5 RESPIRATORY DISEASES

12.6 NEUROLOGY

12.7 ONCOLOGY

12.8 AUTOIMMUNE DISEASE

12.9 DERMATOLOGY

12.1 OPHTHALMOLOGY

12.11 UROLOGY

12.12 OTHERS

13 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS

13.1 OVERVIEW

13.2 DIRECT USERS/PHARMA COMPANIES

13.3 TRADERS/WHOLESALERS/DISTRIBUTORS

13.4 ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONS

14 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY END USER

14.1 OVERVIEW

14.2 API MANUFACTURER

14.3 FINISHED PRODUCT MANUFACTURER

15 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL SALE

15.4 OTHERS

16 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET BY GEOGRAPHY

16.1 MIDDLE EAST & AFRICA

16.1.1 SAUDI ARABIA

16.1.2 SOUTH AFRICA

16.1.3 UAE

16.1.4 ISRAEL

16.1.5 KUWAIT

16.1.6 EGYPT

16.1.7 REST OF MIDDLE EAST & AFRICA

17 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 AUROBINDO PHARMA

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 DIVI’S LABORATORIES LIMITED

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 BASF SE

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 CAMBRIX CORPORATION

19.4.1 COMPANY SNAPSHOT

19.4.2 COMPANY SHARE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENTS

19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 ACETO

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 HIKAL LTD.

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 ALZCHEM GROUP AG

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 VERTELLUS

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT CATEGORIES

19.9.3 RECENT DEVELOPMENTS

19.1 SANOFI

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORFOLIO

19.10.4 RECENT DEVELOPMENTS

19.11 ATUL LTD

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENTS

19.12 AARTI INDUSTRIES LIMITED

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 VASUDHA PHARMA

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 ANYANG GENERAL CHEMICAL CO., LTD.

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 DISHMAN CARBOGEN AMICS LTD

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORFOLIO

19.15.4 RECENT DEVELOPMENTS

19.16 GANESH-GROUP

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENTS

19.17 LEVACHEM COMPANY LIMITED

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 SANDOO PHARMACEUTICALS AND CHEMICALS CO., LTD.

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 SAREX

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENTS

19.2 SUPRIYA LIFESCIENCE LTD.

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Список таблиц

TABLE 1 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: CUSTOMIZATION (COUNTRIES INVOLVED IN IMPORT & EXPORT)

TABLE 2 PERCENTAGE BREAK UP OF COST

TABLE 3 TENTATIVE LAND REQUIREMENT

TABLE 4 PERCENTAGE BREAK UP OF PLANT AREA

TABLE 5 TABLE: 1 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE

TABLE 6 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 7 MARKET PLAYERS OF API INTERMEDIATES

TABLE 8 SALES DATA OF API INTERMEDIATES FOR 2019/2020

TABLE 9 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA VETERINARY DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA NITRILES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA BROMO COMPOUND IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA CHIRAL PCBHP IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA CHLORPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA BROMPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA PHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA O-BENZYL SALBUTAMOL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA BISOPROLOL BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA HEMISULFATE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA OXIRANE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA MEPYRAMINE/PYRILAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA THEOFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA ACEFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA XANTHINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA 6-AMINO-1, 3-DIMETHYL URACIL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA METABOLIC DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICAINFECTIOUS DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA RESPIRATORY DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA NEUROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA ONCOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA DERMATOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA OPHTHALMOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA UROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA DIRECT USERS/PHARMA COMPANIES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA TRADERS/WHOLESALERS/DISTRIBUTORS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA API MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA FINISHED PRODUCT MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA DIRECT TENDER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA RETAIL SALES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA OTHERSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 59 SAUDI ARABIA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 60 SAUDI ARABIA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 61 SAUDI ARABIA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 62 SAUDI ARABIA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 63 SAUDI ARABIA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 64 SAUDI ARABIA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 67 SOUTH AFRICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 68 SOUTH AFRICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 69 SOUTH AFRICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 70 SOUTH AFRICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 71 UAE API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 72 UAE API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 73 UAE API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 74 UAE API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 75 UAE API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 76 UAE API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 77 ISRAEL API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 ISRAEL API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 79 ISRAEL API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 80 ISRAEL API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 81 ISRAEL API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 82 ISRAEL API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 83 KUWAIT API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 84 KUWAIT API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 85 KUWAIT API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 86 KUWAIT API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 87 KUWAIT API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 88 KUWAIT API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 89 EGYPT API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 EGYPT API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 91 EGYPT API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 92 EGYPT API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)

TABLE 93 EGYPT API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 EGYPT API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 REST OF MIDDLE EAST & AFRICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)

Список рисунков

FIGURE 1 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: MARKET TYPE COVERAGE GRID

FIGURE 11 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: SEGMENTATION

FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING IS DRIVING THE MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 PHARMACEUTICAL / BULK DRUG INTERMEDIATES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET

FIGURE 15 TOP 5 COUNTRIES FOR NUMBER OF PEOPLE AGED 20 TO 79 SUFFERING FROM DIABETES IN 2019

FIGURE 16 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN FEMALE POPULATION IN 2020

FIGURE 17 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN MALE POPULATION IN 2020

FIGURE 18 MIDDLE EAST AND AFRICA CAUSES OF DEATHS WITH THE CHRONIC DISEASES 

FIGURE 19 NUMBER OF PERSON AGED 60 YEARS OR OVER BY REGIONS IN 2020 (IN MILLIONS)

FIGURE 20 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)

FIGURE 21 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, 2021

FIGURE 22 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, 2019-2028 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 24 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, 2021

FIGURE 26 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, 2019-2028 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, CAGR(2021-2028)

FIGURE 28 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2021

FIGURE 30 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

FIGURE 31 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, CAGR (2021-2028)

FIGURE 32 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2021

FIGURE 34 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2019-2028 (USD MILLION)

FIGURE 35 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, CAGR (2021-2028)

FIGURE 36 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY CUSTOMERS, LIFELINE CURVE

FIGURE 37 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, 2021

FIGURE 38 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, 2019-2028 (USD MILLION)

FIGURE 39 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, CAGR (2021-2028)

FIGURE 40 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY END USER, LIFELINE CURVE

FIGURE 41 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 42 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

FIGURE 43 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 44 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 45 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: SNAPSHOT (2020)

FIGURE 46 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY COUNTRY (2020)

FIGURE 47 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY COUNTRY (2021 & 2028)

FIGURE 48 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY COUNTRY (2020 & 2028)

FIGURE 49 MIDDLE EAST & AFRICA API INTERMEDIATES MARKET: BY TYPE (2021-2028)

FIGURE 50 MIDDLE EAST AND AFRICA API INTERMEDIATES MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.